Biotech Targets in Prime Merger Environment - FBR & Co

FBR & Co sees strong appeal for the following potential primary targets for others firms that may be looking to make acquisitions: Tesaro (NASDAQ: TSRO), Agile Therapeutics (NASDAQ: AGRX), Kite Pharma (NASDAQ: KITE), Juno Therapeutics (NASDAQ: JUNO), Acceleron Pharma (NASDAQ: XLRN), Aurinia Pharamceuticals (NASDAQ: AUPH), Geron Corp. (NASDAQ: GERN), Genocea (NASDAQ: GNCA).

Analyst Chris Meekins comments (emphasis ours) "The potential for tax reform and policy changes relative to the FDA could prime the pump for acquisitions of clinical-stage biotech companies by Big Pharma. With a likely increase in mergers, we believe certain companies in our coverage universe are prime targets. We expect M&A to be made in multiple therapeutic areas, particularly rare orphan diseases, further demonstrated by three acquisition moves made since mid January by Eli Lilly, Johnson & Johnson, and Allergan."

You May Also Be Interested In

• Bark Inc. (BARK) PT Raised to $19 at Jefferies Following 20:1 Reverse Split
• Stifel Starts ORIC Pharmaceuticals (ORIC) at Buy
• Bernstein SocGen Group Starts Keurig Dr Pepper (KDP) at Outperform, 'outstanding Functional Beverages portfolio'